ACADIA Pharmaceuticals Inc. vs Hilton Hotels Corporation Common Stock — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Hilton Hotels Corporation Common Stock trades at $316.39 (market cap $70.82B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 14× ACADIA Pharmaceuticals Inc.'s market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HLT | |
|---|---|---|
Market Cap | $5.07B | $70.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $350.22 |
52-Week Low | $20.06 | $256.75 |
Enterprise Value | $4.19B | $83.83B |
Dividend Yield | — | 0.19% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →